Abstract
Introduction: Subjective cognitive decline (SCD) can be considered as the preclinical manifestation of Alzheimer's disease (AD). The National Institute on Aging and the Alzheimer's Association criteria for preclinical AD proposed that subtle cognitive changes appear along with AD biomarkers in the late stage of preclinical AD. The objective of this study was to explore whether subtle cognitive impairment (SCI) in individuals with SCD is associated with brain amyloid-β (Aβ) status and SCD severity. Methods: One hundred twenty individuals with SCD (mean age: 70.87 ± 6.10 years) were included in this study. SCI was defined as performance ≤ -1.0 SD on at least two neuropsychological tests. Participants underwent an amyloid positron emission tomography, which was assessed visually and quantitatively using standardized uptake value ratio (SUVR). The severity of SCD was assessed using two self-reported questionnaires: the SCD questionnaire based on the SCD-plus features and the Korean-Everyday Cognition (K-ECog) scale. Results: SCD individuals with SCI (n = 25) had more Aβ positivity than the SCD only group (n = 95) (44% vs. 15.79%; p = 0.002). In addition, the SCI group had a higher global SUVR than the SCD only group (p = 0.048). For self-reported questionnaires, there were no differences in SCD questionnaire total scores and K-ECog global and cognitive domain-specific scores between two groups. Conclusions: In SCD individuals, SCI was associated with higher Aβ positivity, but not with the severity of self-reported cognitive decline, compared to the SCD only group. These results suggest that the recognition of objectively defined subtle cognitive deficits may contribute to the early identification of AD in SCD.
Original language | English |
---|---|
Pages (from-to) | 159-167 |
Number of pages | 9 |
Journal | Dementia and Geriatric Cognitive Disorders |
Volume | 51 |
Issue number | 2 |
DOIs | |
State | Published - 1 Jun 2022 |
Bibliographical note
Funding Information:This study was supported by a grant from the Ministry of Health and Welfare, HI18C0530. The funder had no role in study design; collection, analysis, and interpretation of data; writing of the report; and any restrictions regarding the submission of the report.
Publisher Copyright:
© 2022
Keywords
- Alzheimer's disease
- Amyloid-β
- Subjective cognitive decline
- Subtle cognitive impairment